Shixue Chen
Impact in
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- PARP inhibition in cancer therapy
- Lung Cancer Research Studies
- Building and Construction top 10%
- Structural Behavior of Reinforced Concrete
Papers in
- Oncology 10
- Cancer Immunotherapy and Biomarkers 6
- Pancreatic and Hepatic Oncology Research 2
- Co-authors
- Xudong Chen (2 shared papers)Jikai Zhou (2 shared papers)Junxun Ma (11 shared papers)Pengfei Cui (11 shared papers)Jinliang Wang (8 shared papers)Zhaozhen Wu (10 shared papers)Haitao Tao (9 shared papers)Ziwei Huang (7 shared papers)
- Journals
- Cancer Immunology Immunotherapy (3 papers)Journal of Clinical Oncology (3 papers)Frontiers in Chemistry (2 papers)Therapeutic Advances in Medical Oncology (1 paper)ChemistryOpen (1 paper)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Shixue Chen
26 papers receiving 591 citations
Peers
Comparison fields: 5 of 80
- Oncology 261
- Building and Construction 93
- Civil and Structural Engineering 105
- Immunology 74
- Pulmonary and Respiratory Medicine 86
Countries citing papers authored by Shixue Chen
This map shows the geographic impact of Shixue Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shixue Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shixue Chen more than expected).
Fields of papers citing papers by Shixue Chen
This network shows the impact of papers produced by Shixue Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shixue Chen. The network helps show where Shixue Chen may publish in the future.
Co-authors
The 25 scholars most cited alongside Shixue Chen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 91 | |
| 2 | 2011 | 74 | |
| 3 | 2022 | 52 | |
| 4 | 2021 | 49 | |
| 5 | 2012 | 40 | |
| 6 | 2019 | 39 | |
| 7 | 2020 | 29 | |
| 8 | 2020 | 25 | |
| 9 | 2020 | 25 | |
| 10 | 2022 | 24 | |
| 11 | 2020 | 23 | |
| 12 | 2021 | 21 | |
| 13 | 2017 | 18 | |
| 14 | 2021 | 16 | |
| 15 | 2015 | 12 | |
| 16 | 2019 | 11 | |
| 17 | Efficacy and safety of crizotinib plus bevacizumab in ALK/ROS-1/c-MET positive non-small cell lung cancer: an open-label, single-arm, prospective observational study. | 2021 | 11 |
| 18 | 2021 | 10 | |
| 19 | 2021 | 9 | |
| 20 | 2020 | 7 |
About Shixue Chen
Shixue Chen is a scholar working on Oncology, Organic Chemistry, Molecular Biology, Surgery and Pulmonary and Respiratory Medicine, having authored 27 papers that have together received 601 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Phytochemicals and Antioxidant Activities (2 papers), Innovative concrete reinforcement materials (2 papers), Gout, Hyperuricemia, Uric Acid (2 papers), Structural Behavior of Reinforced Concrete (2 papers), Monoclonal and Polyclonal Antibodies Research (2 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Oncology (261 citations), Building and Construction (93 citations), Civil and Structural Engineering (105 citations), Immunology (74 citations) and Pulmonary and Respiratory Medicine (86 citations). Shixue Chen has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Xudong Chen, Jikai Zhou, Junxun Ma, Pengfei Cui, Jinliang Wang, Zhaozhen Wu, Haitao Tao, Ziwei Huang, Di Huang and Yuanyong Yao. Their work appears in journals such as Cancer Immunology Immunotherapy, Journal of Clinical Oncology, Frontiers in Chemistry, Therapeutic Advances in Medical Oncology and ChemistryOpen.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.